Ductal Carcinoma In Situ With Persistent Vaccine-Related Lymph Node Swelling
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER-positive, PR-positive
- Sex
- Female
- Treatment
- surgery and reconstruction
Treatment course, step by step
- Underwent total left mastectomy with sentinel lymph node removal and immediate DIEP-flap reconstruction.
- No additional cancer treatment was given after surgery.
What happened, in summary
A 59-year-old woman undergoing routine breast screening was found to have a broad area of calcifications in the left breast. Biopsy showed low-to-intermediate grade ductal carcinoma in situ, or DCIS. At the same time, imaging showed abnormal lymph nodes, raising concern because DCIS alone would not usually explain nodal spread.
Several months earlier, she had developed left supraclavicular swelling shortly after receiving a COVID-19 vaccine in the same arm. Biopsy of an abnormal axillary node showed reactive lymphoid tissue rather than cancer, and the clinical team concluded that the persistent lymph-node enlargement was most likely vaccine-related. MRI did not show gross invasive breast cancer.
Because the DCIS involved a large area of the breast, she underwent a total left mastectomy with sentinel lymph node removal and immediate DIEP-flap reconstruction. Final pathology showed multifocal intermediate-grade DCIS that was estrogen- and progesterone-receptor positive. The sentinel node was negative for malignancy. She recovered without complications and did not receive additional cancer treatment.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- ER Positive Breast Cancer 242 stories
- DIEP flap for Breast Cancer 23 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer